Alizé and Lilly sign type 2 diabetes pact
This article was originally published in Scrip
Executive Summary
Lilly has agreed to collaborate with the privately held French firm Alizé Pharma on the development of its unacylated ghrelin agonists for the treatment of type 2 diabetes.